Document is current
Any future updates will be listed below
-
Authors
Chen, Ping
Li, Jingyi
Telezhkin, Vsevolod
Gu, Yu
Tao, Min
Guo, Liping
Song, Simin
Dong, Rihe
Luo, Xianyang
Wang, Yan
Liu, Qian
Tian, Weiming
Meng, Weihua
Hong, Wei
Song, Bing
-
Funding
Funding for this research was provided by:
Key Technologies Research and Development Program (2024YFF206402)
National Natural Science Foundation of China (T2350710233, 32471010, 32100800)
the Chinese Academy of Sciences President’s International Fellowship Initiative (2022VBB0002)
Shenzhen Science and Technology Program (JCYJ20220818101404009, JCYJ20220818100802005)
Shenzhen Science and Technology Program (KQTD20210811090117032)
the Shenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases (ZDSYS20220304163558001)
Pioneer and Leading Goose R&D Program of Zhejiang Province (2023C04049)
International Cooperation Project of Ningbo City (2023H025)
the Guangdong Science and Technology Program (2021QN02Y925)
- License Information
-
More Information
Article History
Received: 11 February 2025
Accepted: 16 June 2025
First Online: 26 July 2025
Declarations
:
: The DYR0100 human iPSCs (origin of background: HFF-1, SCRC1041 foreskin fibroblast cell line) were obtained from the Stem Cell Bank at the Chinese Academy of Sciences and were procured through National Collection of Authenticated Cell Cultures. The Stem Cell Bank has confirmed that there was initial ethical approval for the collection of human cells and that the donors had signed informed consent.
: Not applicable.
: The authors declare that they have no competing interests.
